Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a note issued to investors on Tuesday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Down 1.4 %

NYSE:BTX opened at $0.30 on Tuesday. The firm has a market capitalization of $17.82 million, a price-to-earnings ratio of -0.13 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a twelve month low of $0.17 and a twelve month high of $10.10. The stock’s 50 day moving average price is $0.34 and its two-hundred day moving average price is $0.88.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.